Internal Medicine, Hematology & Oncology · Grosse Pointe Woods, MI
NPI
1740302850
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
19229 Mack Ave, Suite 24
Grosse Pointe Woods, MI, 48236
Phone (313) 884-5522
Groups this clinician bills Medicare through
Medicare paid, 2024
$82K
1,403 services
Medicare patients, 2024
409
Average age 73
Drug cost, 2024
$8.0M
1,831 prescriptions
Company payments, 2025
$21K
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel Lebovic was code 99214 (office e&m - established), 405 times for 160 patients. In total Daniel Lebovic billed 1,403 services in 19 codes, and Medicare paid $82K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-05-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 405 | 160 | $71.12 | $29K |
| 99213 Office E&M - Established | Facility | 186 | 109 | $48.16 | $8,958 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 178 | 68 | $12.93 | $2,302 |
| 99214 Office E&M - Established | Office | 167 | 66 | $71.96 | $12K |
| 99232 Hospital E&M - Subsequent | Facility | 112 | 58 | $62.95 | $7,051 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 90 | 36 | $13.08 | $1,178 |
| 99223 Hospital E&M - Initial | Facility | 74 | 63 | $135.69 | $10K |
| 99213 Office E&M - Established | Office | 69 | 43 | $45.43 | $3,134 |
| 99204 Office E&M - New | Facility | 33 | 33 | $87.88 | $2,900 |
| 99233 Hospital E&M - Subsequent | Facility | 20 | 12 | $95.23 | $1,905 |
| 99441 Telephone Services | Facility | 18 | 15 | $21.92 | $395 |
| 99204 Office E&M - New | Office | 11 | 11 | $73.94 | $813 |
By year: 2022 $81K for 1,208 services; 2023 $84K for 1,190 services; 2024 $82K for 1,403 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel Lebovic prescribed most often to Medicare patients was Acyclovir, with 215 prescriptions and refills. In total Daniel Lebovic wrote 1,831 Medicare prescriptions that cost $8.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 215 | 338 | 49 | $3,282 |
| Eliquis Apixaban | 152 | 226 | 38 | $125K |
| Hydroxyurea Generic | 140 | 253 | 32 | $3,699 |
| Revlimid Lenalidomide | 97 | 97 | 17 | $1.6M |
| Dexamethasone Generic | 88 | 112 | 26 | $1,499 |
| Lenalidomide Generic | 77 | 77 | Under 11 | $980K |
| Imbruvica Ibrutinib | 64 | 64 | Under 11 | $934K |
| Venclexta Venetoclax | 54 | 54 | Under 11 | $618K |
| Sandostatin Lar Depot Octreotide Acetate,mi-Spheres | 52 | 52 | Under 11 | $309K |
| Warfarin Sodium Generic | 47 | 83 | Under 11 | $571 |
| Gabapentin Generic | 45 | 57 | 12 | $267 |
| Brukinsa Zanubrutinib | 45 | 45 | Under 11 | $511K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 45 | 95 | 15 | $240 |
| Potassium Chloride Generic | 44 | 69 | Under 11 | $672 |
| Imatinib Mesylate Generic | 40 | 40 | Under 11 | $19K |
Brand drugs: - claims; generic drugs: 1,125 claims; opioid claims: 31.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel Lebovic $21K ($21K in general payments such as food, travel and fees) from 7 companies. The largest payer was Genzyme Corporation with $14K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.